GLPwatch
Papers (12034)
Page 173 of 201, ranked by citation count.
- Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.
- Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
- Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.
- Pirfenidone alone or combined with either dulaglutide or empagliflozin protects against fructose-induced Parkinsonian features in rats.
- Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.
- Maintaining weight loss with tirzepatide . . . and other research.
- Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study.
- Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
- Toxicity of Semaglutide upon sub chronic administration in Rabbits.
- Tirzepatide Safely Reduces Blood Glucose, Weight in Type 2 Diabetes.
- The use of tirzepatide to successfully treat persistent genital arousal disorder/genitopelvic dysesthesia: a case report.
- Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
- GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.
- Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
- CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
- Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
- Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report.
- Exercise-induced anaphylaxis with a cofactor of GIP/GLP-1 receptor agonist: A case report.
- Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?
- Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
- Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
- Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.
- Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment.
- Neuropsychiatric side effects of semaglutide in patients with dementia.
- Tirzepatide drives weight loss in people with obesity due to MC4R deficiency.
- Liquid Chromatography Evaluation of a Novel Graphitic Carbon Stationary Phase Using Glucagon-Like Peptide‑1 Analogs.
- [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
- Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.
- Exenatide Attenuates Doxorubicin-Induced Acute Hepatic Injury Through Modulation of SIRT1-HMGB1 Signaling and Oxidative Stress.
- Tirzepatide-Induced Functional Small Bowel Obstruction in a Surgically Naïve Patient: A Case Report.
- Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.
- Association of Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists with Incident Glaucoma in Patients with Type 2 Diabetes: A Retrospective Cohort Study.
- Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
- Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.
- Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
- Short-term effect of tirzepatide on serum calcitonin in adults with obesity.
- Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.
- [EFFECTS OF ORALLY AND PARENTERALLY ADMINISTERED ANALOGS OF PEPTIDE HORMONES ON RENAL WATER AND ION TRANSPORT].
- Probable tirzepatide-associated limbic encephalitis with status epilepticus in a patient with extreme obesity: a case report.
- Severe diabetic ketoacidosis associated with insulin dose reduction after tirzepatide initiation.
- A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.
- Response to the Letter by Kalra S. et al.
- Chemoenzymatic Synthesis of Rhamnolipid-Modified Exendin-4: A Dual Approach for Long-Acting Glycemic Control through Endogenous Antibody Recruitment and Albumin Interaction.
- Exendin-4 improves neurodevelopmental outcome after neonatal germinal matrix hemorrhage.
- Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea.
- Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
- Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.
- Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
- Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?
- Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.
- Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide.
- Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.
- Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.
- Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure.
- Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.
- Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.
- Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health?
- Prediction of the optimal dose of exenatide in patients with type 2 diabetes mellitus with renal impairment using physiologically based pharmacokinetic modeling.
- Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.
- Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.